Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Aclara Biosciences, Inc. (NasdaqNM:ACLA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
1288 Pear Avenue
Mountain View, CA 94043
Phone: (650) 210-1200
Fax: (650) 210-1210
Email: info@aclara.com
Employees (last reported count): 124
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Technology
 ·Industry: Scientific & Technical Instr.
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 58%
·Institutional: 38% (91% of float)
(149 institutions)
·Net Inst. Buying: 895.0K shares (+6.17%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Aclara Biosciences, Inc. is a microfluidics, or lab-on-a-chip, company with access to a wide range of technology and intellectual property required to broadly address the genomics and pharmaceutical drug screening markets. The Company is developing multiple products based on its proprietary microfluidics technology that allow researchers to rapidly perform large numbers of chemical and biological measurements in a miniaturized, automated format. In collaboration with its strategic partners, the Company is developing dedicated analytical instruments that will utilize its LabCard chip products and assay chemistries. These LabCard systems are expected to provide order-of-magnitude increases in throughput and enhanced accuracy for a wide range of laboratory analyses. The Company introduced its initial LabCard product, the Arteas microfluidic array chip, in late 2000.
More from Market Guide: Expanded Business Description

Financial Summary
ACLA is a developer of microfluidics, or lab-on-a-chip, technology with access to technology and intellectual property required to address the markets for genomics, or RNA and DNA analysis and pharmaceutical drug screening. For the six months ended 6/30/01, revenue fell less than 1% to $1.8 million. Net loss rose 20% to $13 million. Results reflect a decrease in collaboration revenues from Applied Biosystems Group and Cellomics, and a $2.4 million litigation settlement expense.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Thomas Baruch, J.D.
Chairman
--  --  
Joseph Limber, 48
Pres, CEO, Director
$516K$12.6M
Herbert Hooper, Ph.D., 37
Exec. VP, CTO
248K1.9M
Dennis Harris, Ph.D.
Sr. VP, R&D
--  --  
Danny Morrow, 51
VP-Operations
99K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ACLAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$4.313
Recent Price$6.19 
52-Week High
on 1-Sep-2000
$39.75 
Daily Volume (3-month avg)125.8K
Daily Volume (10-day avg)40.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-83.7%
52-Week Change
relative to S&P500
-78.1%
Share-Related Items
Market Capitalization$221.2M
Shares Outstanding35.7M
Float15.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.62 
Earnings (ttm)-$1.78 
Earnings (mrq)-$0.09 
Sales (ttm)$0.10 
Cash (mrq)$3.89 
Valuation Ratios
Price/Book (mrq)1.34 
Price/EarningsN/A 
Price/Sales (ttm)61.41 
Income Statements
Sales (ttm)$3.46M
EBITDA (ttm)-$66.9M
Income available to common (ttm)-$60.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-29.62%
Return on Equity (ttm)-33.26%
Financial Strength
Current Ratio (mrq)34.19 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$139.0M
Short Interest
As of 8-Aug-2001
Shares Short255.0K
Percent of Float1.7%
Shares Short
(Prior Month)
399.0K
Short Ratio2.22 
Daily Volume115.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.